CASI Pharmaceuticals Secures FDA Clearance for CID-103 IND Application in Renal Allograft Antibody-Mediated Rejection

Reuters

08/04

CASI Pharmaceuticals Secures FDA Clearance for CID-103 IND Application in Renal Allograft Antibody-Mediated Rejection

CASI Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug $(IND.AU)$ application for CID-103, an anti-CD38 monoclonal antibody intended to treat renal allograft antibody-mediated rejection $(AMR)$. This clearance marks a significant milestone for CASI Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for organ transplant rejection and autoimmune diseases. The upcoming Phase 1 clinical trial will focus on evaluating the safety, tolerability, and efficacy of CID-103 in adults with active and chronic active renal allograft AMR. The study aims to address the urgent need for new therapeutic options for patients with resistant AMR, a leading cause of kidney transplant loss.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1056000) on August 04, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2556138384"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2556138384\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2556138384?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2556138384","market":"us","top_or_hot":-1,"title":"CASI Pharmaceuticals Secures FDA Clearance for CID-103 IND Application in Renal Allograft Antibody-Mediated Rejection","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CASI Pharmaceuticals Secures FDA Clearance for CID-103 IND Application in Renal Allograft Antibody-Mediated Rejection\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CASI Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> application for CID-103, an anti-CD38 monoclonal antibody intended to treat renal allograft antibody-mediated rejection <a href=\"https://laohu8.com/S/AMR\">$(AMR)$</a>. This clearance marks a significant milestone for CASI Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for organ transplant rejection and autoimmune diseases. The upcoming Phase 1 clinical trial will focus on evaluating the safety, tolerability, and efficacy of CID-103 in adults with active and chronic active renal allograft AMR. The study aims to address the urgent need for new therapeutic options for patients with resistant AMR, a leading cause of kidney transplant loss.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1056000) on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CASI Pharmaceuticals Secures FDA Clearance for CID-103 IND Application in Renal Allograft Antibody-Mediated Rejection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCASI Pharmaceuticals Secures FDA Clearance for CID-103 IND Application in Renal Allograft Antibody-Mediated Rejection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-04 21:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CASI Pharmaceuticals Secures FDA Clearance for CID-103 IND Application in Renal Allograft Antibody-Mediated Rejection\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CASI Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug <a href=\"https://laohu8.com/S/IND.AU\">$(IND.AU)$</a> application for CID-103, an anti-CD38 monoclonal antibody intended to treat renal allograft antibody-mediated rejection <a href=\"https://laohu8.com/S/AMR\">$(AMR)$</a>. This clearance marks a significant milestone for CASI Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for organ transplant rejection and autoimmune diseases. The upcoming Phase 1 clinical trial will focus on evaluating the safety, tolerability, and efficacy of CID-103 in adults with active and chronic active renal allograft AMR. The study aims to address the urgent need for new therapeutic options for patients with resistant AMR, a leading cause of kidney transplant loss.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1056000) on August 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CASI","symbol_name":"凯信远达","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250804:nNDL9RcsWh:1","article_id":"2556138384","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556138384","pubTimestamp":1754312436,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CASI Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration  has cleared its Investigational New Drug  application for CID-103, an anti-CD38 monoclonal antibody intended to treat renal allograft antibody-mediated rejection . This clearance marks a significant milestone for CASI Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for organ transplant rejection and autoimmune diseases. The upcoming Phase 1 clinical trial will focus on evaluating the safety, tolerability, and efficacy of CID-103 in adults with active and chronic active renal allograft AMR. The study aims to address the urgent need for new therapeutic options for patients with resistant AMR, a leading cause of kidney transplant loss.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pur","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CASI":"凯信远达","BK4139":"生物科技"},"translate_title":"CASI Pharmaceuticals获得FDA批准CID-103 IND申请治疗同种异体肾移植抗体介导的排斥反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CASI":0.9},"content_text":"CASI Pharmaceuticals Secures FDA Clearance for CID-103 IND Application in Renal Allograft Antibody-Mediated Rejection\n    \n\n        CASI Pharmaceuticals Inc. has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug $(IND.AU)$ application for CID-103, an anti-CD38 monoclonal antibody intended to treat renal allograft antibody-mediated rejection $(AMR)$. This clearance marks a significant milestone for CASI Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for organ transplant rejection and autoimmune diseases. The upcoming Phase 1 clinical trial will focus on evaluating the safety, tolerability, and efficacy of CID-103 in adults with active and chronic active renal allograft AMR. The study aims to address the urgent need for new therapeutic options for patients with resistant AMR, a leading cause of kidney transplant loss.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CASI Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1056000) on August 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}